Functional proteomic insights in B-cell chronic lymphocytic leukemia

Abstract

B cell chronic lymphocytic leukemia (B-CLL) is a hematological malignancy considered as the most common leukemia in the Western world. The understanding of B cell differentiation is crucial for the diagnosis, prognosis, and treatment of the disease. Areas covered: In this review, B-cell ontogeny and its relation with the CLL development, in combination with the proteomic approaches which could provide a deep characterization of the disease through the characterization of the cellular signaling pathways involved in the pathological cells is described. Expert commentary: Although conventional strategies (genome sequencing, morphology assays, and immunophenotyping by flow cytometry and/or immunochemistry) have allowed the establishment of the disease stage based on different parameters, it is still necessary to utilize novel approaches (e.g., proteomics) that have the potential to simultaneously analyze thousands of molecules to improve understanding of CLL.

A systematic approach for peptide characterization of B-cell receptor in chronic lymphocytic leukemia cells

“…Specifically, the disrupted activation of the BCR appears as the responsible of the chronic lymphocytic leukemia (CLL) [7, 8]. This disease, characterized by its high heterogeneity, is the most common human blood cancer in Western countries and it usually shows a monoclonal expansion of an aberrant B-cell clone [9, 10].…”

Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation

“…Several studies have previously employed MS proteomics in the analysis of CLL (recently reviewed (19,20)); with the latest, a characterisation of 9 U-CLL versus 9 M-CLL, identifying 3521 and relatively profiling 2024 proteins, of which approximately 100 proteins were differentially expressed (±1.5-fold change, p<0.05) (21).…”

Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells

“…B-cell chronic lymphocytic leukemia (CLL) is one of the most common forms of blood cancers 1 , 2 . The incidence of CLL in the western world is 4.2/100 000 per year.…”